Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, April 7, 2026 -- Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March 27 in The Lancet HIV.

Y. Joseph Hwang, M.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the effect of switching to INSTIs on incident diabetes in antiretroviral therapy-experienced people with HIV. The analysis included individual-level data from 27 longitudinal cohorts of adults with HIV in the United States and Canada without diabetes who had used non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors for at least 180 days (in 2016 to 2022) but had never used an INSTI.

The researchers identified 13,071 participants with 2,702 encounters in which they switched to an INSTI from an NNRTI, 54,766 in which they continued an NNRTI, 1,714 in which they switched to an INSTI from a protease inhibitor, and 26,599 in which they continued a protease inhibitor. Incident diabetes risk increased with switching from protease inhibitors to INSTIs (adjusted hazard ratio [aHR], 1.38; 95 percent confidence interval [CI], 1.06 to 1.80), in contrast to a nonsignificant increase in incident diabetes risk when switching from NNRTIs to INSTIs (aHR, 1.10; 95 percent CI, 0.87 to 1.39). During the first two years after switching from protease inhibitors to INSTIs, diabetes risk was higher (HR, 1.67; 95 percent CI, 1.21 to 2.30), but not thereafter. Weight gain did not explain the effect of switching from protease inhibitors to INSTIs on diabetes. When examining participants with weight gain of 5 percent or less in the first year after, the switch from protease inhibitors to INSTIs had an HR of 1.37 (95 percent CI, 1.02 to 1.84), and the switch from NNRTIs to INSTIs had an HR of 1.03 (95 percent CI, 0.79 to 1.36).

"These findings help people with HIV make informed decisions when switching medications," Hwang said in a statement. "Our analysis is not intended to discourage switching medications, but rather to inform patients and their treating clinicians of the potential metabolic risks that should be weighed in making individualized treatment decisions in such common clinical scenarios."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-08 01:59

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords